Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells.

Vatakis DN, Koya RC, Nixon CC, Wei L, Kim SG, Avancena P, Bristol G, Baltimore D, Kohn DB, Ribas A, Radu CG, Galic Z, Zack JA.

Proc Natl Acad Sci U S A. 2011 Dec 20;108(51):E1408-16. doi: 10.1073/pnas.1115050108. Epub 2011 Nov 28.

2.

Using the BLT humanized mouse as a stem cell based gene therapy tumor model.

Vatakis DN, Bristol GC, Kim SG, Levin B, Liu W, Radu CG, Kitchen SG, Zack JA.

J Vis Exp. 2012 Dec 18;(70):e4181. doi: 10.3791/4181.

3.

Introduction of exogenous T-cell receptors into human hematopoietic progenitors results in exclusion of endogenous T-cell receptor expression.

Vatakis DN, Arumugam B, Kim SG, Bristol G, Yang O, Zack JA.

Mol Ther. 2013 May;21(5):1055-63. doi: 10.1038/mt.2013.28. Epub 2013 Mar 12.

4.

T-cell receptor gene therapy targeting melanoma-associated antigen-A4 inhibits human tumor growth in non-obese diabetic/SCID/γcnull mice.

Shirakura Y, Mizuno Y, Wang L, Imai N, Amaike C, Sato E, Ito M, Nukaya I, Mineno J, Takesako K, Ikeda H, Shiku H.

Cancer Sci. 2012 Jan;103(1):17-25. doi: 10.1111/j.1349-7006.2011.02111.x. Epub 2011 Nov 8.

5.

Sustained transgene expression by human cord blood derived CD34+ cells transduced with simian immunodeficiency virus agmTYO1-based vectors carrying the human coagulation factor VIII gene in NOD/SCID mice.

Kikuchi J, Mimuro J, Ogata K, Tabata T, Ueda Y, Ishiwata A, Kimura K, Takano K, Madoiwa S, Mizukami H, Hanazono Y, Kume A, Hasegawa M, Ozawa K, Sakata Y.

J Gene Med. 2004 Oct;6(10):1049-60. Erratum in: J Gene Med. 2005 Jun;7(6):836. Kimura, Konzoh [corrected to Kimura, Kouzoh].

PMID:
15386735
6.

Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells.

Yang L, Baltimore D.

Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4518-23. Epub 2005 Mar 9.

7.

CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors.

Hanson HL, Kang SS, Norian LA, Matsui K, O'Mara LA, Allen PM.

J Immunol. 2004 Apr 1;172(7):4215-24.

8.

Human allogeneic stem cell maintenance and differentiation in a long-term multilineage SCID-hu graft.

Fraser CC, Kaneshima H, Hansteen G, Kilpatrick M, Hoffman R, Chen BP.

Blood. 1995 Sep 1;86(5):1680-93.

9.

Novel CD8+ T cell-based vaccine stimulates Gp120-specific CTL responses leading to therapeutic and long-term immunity in transgenic HLA-A2 mice.

Nanjundappa RH, Wang R, Xie Y, Umeshappa CS, Xiang J.

Vaccine. 2012 May 21;30(24):3519-25. doi: 10.1016/j.vaccine.2012.03.075. Epub 2012 Apr 6.

PMID:
22484292
10.

Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling.

Zhao Y, Parkhurst MR, Zheng Z, Cohen CJ, Riley JP, Gattinoni L, Restifo NP, Rosenberg SA, Morgan RA.

Cancer Res. 2007 Mar 15;67(6):2425-9.

11.

Active form of Notch imposes T cell fate in human progenitor cells.

De Smedt M, Reynvoet K, Kerre T, Taghon T, Verhasselt B, Vandekerckhove B, Leclercq G, Plum J.

J Immunol. 2002 Sep 15;169(6):3021-9.

13.

Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2r gamma(null) humanized mice.

Shultz LD, Saito Y, Najima Y, Tanaka S, Ochi T, Tomizawa M, Doi T, Sone A, Suzuki N, Fujiwara H, Yasukawa M, Ishikawa F.

Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13022-7. doi: 10.1073/pnas.1000475107. Epub 2010 Jul 6.

14.

In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells.

Kitchen SG, Levin BR, Bristol G, Rezek V, Kim S, Aguilera-Sandoval C, Balamurugan A, Yang OO, Zack JA.

PLoS Pathog. 2012;8(4):e1002649. doi: 10.1371/journal.ppat.1002649. Epub 2012 Apr 12.

15.

Human CD8+ memory and EBV-specific T cells show low alloreactivity in vitro and in CD34+ stem cell-engrafted NOD/SCID/IL-2Rγc null mice.

Thomas S, Klobuch S, Sommer M, van Ewijk R, Theobald M, Meyer RG, Herr W.

Exp Hematol. 2014 Jan;42(1):28-38.e1-2. doi: 10.1016/j.exphem.2013.09.013. Epub 2013 Oct 8.

PMID:
24120693
16.

Examination of thymic positive and negative selection by flow cytometry.

Hu Q, Nicol SA, Suen AY, Baldwin TA.

J Vis Exp. 2012 Oct 8;(68). pii: 4269. doi: 10.3791/4269.

17.

HSV-sr39TK positron emission tomography and suicide gene elimination of human hematopoietic stem cells and their progeny in humanized mice.

Gschweng EH, McCracken MN, Kaufman ML, Ho M, Hollis RP, Wang X, Saini N, Koya RC, Chodon T, Ribas A, Witte ON, Kohn DB.

Cancer Res. 2014 Sep 15;74(18):5173-83. doi: 10.1158/0008-5472.CAN-14-0376. Epub 2014 Jul 18.

18.

Molecular evidence of lentiviral vector-mediated gene transfer into human self-renewing, multi-potent, long-term NOD/SCID repopulating hematopoietic cells.

Ailles L, Schmidt M, Santoni de Sio FR, Glimm H, Cavalieri S, Bruno S, Piacibello W, Von Kalle C, Naldini L.

Mol Ther. 2002 Nov;6(5):615-26.

19.

Human CD34+ fetal liver stem cells differentiate to T cells in a mouse thymic microenvironment.

Plum J, De Smedt M, Defresne MP, Leclercq G, Vandekerckhove B.

Blood. 1994 Sep 1;84(5):1587-93.

20.

Supplemental Content

Support Center